EXTON, PA--(MARKET WIRE)--Apr 23, 2007 -- Rheologics Technologies Inc. ("Rheologics" or the "Company") (Other OTC:RTGI.PK - News), the leader in the study of blood viscosity and its relationship to cardiovascular disease, announces plans for a multi-center clinical study on the variability of whole blood viscosity.
Whole blood viscosity has been studied for over thirty years with approximately 1,000 papers published in peer-reviewed journals during that time period. This body of research has correlated whole blood viscosity to numerous disease conditions such as coronary and carotid artery disease as well as every major cardiac risk factor, including blood pressure, LDL cholesterol, C-reactive protein, age, and type-II diabetes.
With respect to this body of published work, Rheologics is responding to a need for establishing standards for healthy ranges for whole blood viscosity and a clearer understanding of the variability of whole blood viscosity in a broad cross-section of patients.
Rheologics' Chairman & Chief Scientific Officer, Kenneth Kensey, MD, said, "This multi-center study will be a vital foundation for future clinical and pharmacological studies that will require reliable standards for healthy whole blood viscosity, findings that have been historically unavailable in a definitive fashion."
About Rheologics Technologies, Inc.
Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventive diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at www.rheologics.com.